Danaher Corporation (DHR)
After hours:
| Previous close | 254.46 |
| Open | 253.33 |
| Bid | 250.44 x 900 |
| Ask | 251.40 x 900 |
| Day's range | 249.33 - 253.33 |
| 52-week range | 221.22 - 283.63 |
| Volume | |
| Avg. volume | 2,667,409 |
| Market cap | 184.315B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 29.30 |
| EPS (TTM) | 8.52 |
| Earnings date | 18 Oct 2023 - 23 Oct 2023 |
| Forward dividend & yield | 1.08 (0.42%) |
| Ex-dividend date | 11 Oct 2023 |
| 1y target est | 280.65 |
ZacksDanaher (DHR) Stock Moves -0.3%: What You Should Know
Danaher (DHR) closed the most recent trading day at $254.46, moving -0.3% from the previous trading session.
ZacksDanaher (DHR) Stock Sinks As Market Gains: What You Should Know
Danaher (DHR) closed the most recent trading day at $253.77, moving -0.58% from the previous trading session.
- Financial Times
Abcam founder to vote against proposed $5.7bn acquisition by US Danaher
The founder of UK life sciences company Abcam plans to vote against a proposed $5.7bn acquisition by US group Danaher, pushing instead to replace the board and take back the reins as chief executive. Jonathan Milner, who has a 6.1 per cent stake in the Cambridge-based company, argues the $24-a-share deal materially undervalues Abcam, which creates custom antibodies, among other products, for scientists to use in research. Shares in Abcam were trading at $23.36 before the deal was announced in late August, having risen about 40 per cent after Milner launched a campaign for changes on the board in late May.
